Ponatinib for Chronic Myeloid Leukaemia

 What is Iclusig used for?

As a kinase inhibitor Iclusig is recommended for the treatment of adults patients with:

chronic phase chronic myeloid leukemia (CML) who didn't get benefit from treatment with at least 2 prior kinase inhibitor medications. 

accelerated phase or blast phase CML, or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are not able to take any other kinase inhibitor drugs. 

What are the side effects of iclusig? 

The most common side effects of Iclusig may include:

• fever
• nausea
• skin rash 
• joint pain 
• abdomen pain
• headache 
• constipation
• dry skin
• high blood pressure 
• tiredness
• bleeding
• low hemoglobin in the blood 
• liver problems
• low blood platelet counts
• inflammation of the pancreas

Report to your healthcare practitioner in case you experience any side effect that is persistent and bothers you. 

What is the recommended dosage of iclusig? 

The starting dose of Iclusig is 45 mg, which should be given orally once in a day. Reducing the iclusig dosage is considered for patients with chronic phase CML and accelerated phase CML who have achieved a major cytogenetic response. Iclusig tablets should be consumed with or without food. Tablets required to be swallowed whole.

What dosage forms and strength iclusig comes? 

This medication is available in the form of tablets as following strength:

• iclusig 15 mg tablet
• iclusig 30 mg tablet
• iclusig 45 mg tablet

Is ponatinib a chemotherapy drug?

Ponatinib mainly is a type of targeted cancer drug. It is also known by its brand name Iclusig. It blocks as well as interferes with a number of protein kinases. 

What are the drug interactions with iclusig? 

This drug may interact when it is used with other drugs. Some possible iclusig drug interactions are as follows:

Coadministration of carbamazepine, phenytoin, rifampin, and St. John’s Wort (strong CYP3A inducers) together with iclusig tablets must be avoided. 

When using iclusig together with strong CYP3A inhibitors (e.g. ritonavir, indinavir, boceprevir, conivaptan, itraconazole, clarithromycin, nelfinavir, ketoconazole, lopinavir/ritonavir, posaconazole, saquinavir, telaprevir, telithromycin, nefazodone, voriconazole), the recommended initial dose needs to be reduced. 

How much does iclusig cost? 

In India, the cost of iclusig is quite reasonable. The iclusig 45 mg price is around $17,299 for a supply of 30 tablets. Prices may vary depending on branded to non-branded (generic) drugs. 

Where can I get Iclusig at a best price? 

In order to get the best iclusig price, always go with a pharmaceutical wholesaler company that holds the WHO-GDP & ISO certification. 

How should I store Iclusig?

Iclusig tablets should be placed at room temperature between 68°F - 77°F (20°C-25°C). Keep these tablets and all medicines out of the reach of children.

Exkivityt (mobocertinib) Capsules

A kinase inhibitor called EXKIVITY is prescribed for adult patients whose disease has progressed during or following platinum-based chemotherapy and who have locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as determined by an FDA-approved test.

Recommended Dosage:

160 mg taken once daily, with or without food, is the recommended dosage. 

Warnings and Precautions:

Lung and Breathing Problems:

Keep an eye on any new or worsening breathing problems while taking Exkivity. If you have signs like trouble breathing or coughing, tell your doctor right away. They might stop Exkivity if they suspect a lung problem.

Heart Health:

Your heart's health will be checked before and during Exkivity treatment. If there are concerns about how your heart is working, the dosage might change or the medication might be stopped.

Dealing with Diarrhea:

Diarrhea might happen while you're on Exkivity. It could lead to dehydration or issues with your body's balance of minerals. Your doctor might suggest medicine for diarrhea and ask you to drink more fluids. They could adjust the Exkivity dose if it becomes severe.

Pregnancy Precautions:

If you can get pregnant, be aware that Exkivity might harm an unborn baby. It's important to use effective non-hormonal birth control while taking Exkivity to prevent pregnancy.

Documentation & Availability in India:

If you are considering the import of Exkivity (Mobecertinib succinate)  to India, please be aware that Exkivity can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Exkivity will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Exkivity in India: 

Exkivity (Mobecertinib succinate)  is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Exkivity can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Exkivity (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

For inquiries regarding the price of Exkivity in India and to initiate the ordering process, please reach out to us through the following contact details:

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: Indian Pharma Network is proficient in sourcingExkivity (Mobecertinib succinate)  from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ’s

What is Exkivity (Mobocertinib succinate)?

Exkivity, also known as Mobocertinib succinate, is an oral medication used for the treatment of non-small cell lung cancer (NSCLC). Specifically, it targets tumors with certain mutations in the epidermal growth factor receptor (EGFR) gene, such as exon 20 insertion mutations, which are typically resistant to other EGFR inhibitors.

How does Exkivity work?

Exkivity is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of mutated EGFR proteins in cancer cells. EGFR mutations, especially exon 20 insertions, can drive the growth of cancer cells. Exkivity inhibits the abnormal signaling caused by these mutations, thereby slowing down or halting the growth of cancer cells.

What are the common side effects of Exkivity?

Common side effects of Exkivity may include diarrhea, rash, nausea, vomiting, fatigue, decreased appetite, mouth sores, and abdominal pain. Additionally, Exkivity can cause more serious side effects such as interstitial lung disease/pneumonitis, liver problems, and heart problems.

How is Exkivity taken?

Exkivity is taken orally in the form of tablets. The typical recommended dosage is usually once daily with or without food. Dosage and administration may vary based on individual patient factors and should be taken as directed by a healthcare professional.

Who is a candidate for Exkivity treatment?

Exkivity is approved for adult patients with NSCLC that have specific EGFR mutations, particularly exon 20 insertion mutations, and have progressed after previous treatment or are unable to tolerate other EGFR inhibitors. Patients should undergo genetic testing to confirm the presence of these mutations before starting treatment with Exkivity.

Adbry Price in India

Medicinal Uses

Tralokinumab-ldrm injection is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients. This is for individuals whose condition remains inadequately controlled with topical prescription therapies or when these therapies are not advisable. Tralokinumab-ldrm can be used in combination with or without topical corticosteroids.

Recommended Dosage:

Before starting Tralokinumab-ldrm treatment, ensure all age-appropriate vaccinations as recommended by current immunization guidelines are completed. The recommended dosage includes an initial dose of 600 mg (four injections of 150 mg each), followed by 300 mg (two 150 mg injections) administered every other week. For patients below 100 kg achieving clear or almost clear skin after 16 weeks, a dosage of 300 mg every 4 weeks may be considered. Tralokinumab-ldrm is administered through subcutaneous injection.

Warnings and Precautions:

Hypersensitivity: Anaphylaxis and angioedema have been reported after Tralokinumab-ldrm administration. Discontinue Tralokinumab-ldrm in case of hypersensitivity reactions.

Conjunctivitis and Keratitis: Patients should promptly report any new or worsening eye symptoms to their healthcare provider.

Parasitic (Helminth) Infections: Address pre-existing helminth infections before starting Tralokinumab-ldrm. If infections occur during treatment and don't respond to anti-helminth treatment, discontinue Tralokinumab-ldrm until the infection resolves.

Risk of Infection with Live Vaccines: Avoid the use of live vaccines while on Tralokinumab-ldrm treatment.

Documentation & Availability in India:

If you are considering the import of Tralokinumab to India, please be aware that Tralokinumab-ldrm can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

• The order for Elahere will be confirmed upon the receipt of the following documents:
• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Tralokinumab-ldrm in India: 

Tralokinumab is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Tralokinumab-ldrm can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Tralokinumab-ldrm (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

For inquiries regarding the price of Tralokinumab-ldrm in India and to initiate the ordering process, please reach out to us through the following contact details:

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: Indian Pharma Network is proficient in sourcing Tralokinumab-ldrm from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

What is Tralokinumab-ldrm used for?

Tralokinumab-ldrm is an interleukin-13 antagonist prescribed for the treatment of moderate-to-severe atopic dermatitis in adults. It's specifically for patients whose condition isn't adequately controlled with topical prescription therapies or when using those therapies isn't advisable.

How is Tralokinumab-ldrm administered?

Tralokinumab-ldrm is administered through subcutaneous injection. The typical dosage includes an initial dose of 600 mg (four injections of 150 mg each), followed by a maintenance dose of 300 mg (two 150 mg injections) every other week. Some patients achieving clearer skin after 16 weeks might have their dosage adjusted to 300 mg every 4 weeks.

Can Tralokinumab-ldrm be used in combination with other medications?

Tralokinumab-ldrm can be used with or without topical corticosteroids. However, it is not recommended to be used in combination with other JAK inhibitors or certain immunosuppressants.

Are there any conditions where Tralokinumab-ldrm should not be used?

Tralokinumab-ldrm should not be used in individuals with a known hypersensitivity to tralokinumab-ldrm or any components present in the medication.

What precautions should be taken while using Tralokinumab-ldrm?

Some precautions include careful monitoring for hypersensitivity reactions, prompt reporting of new or worsening eye symptoms, treating pre-existing helminth infections before starting Tralokinumab-ldrm, avoiding live vaccines during treatment, and regular check-ups and tests to monitor health during treatment.